Antibody tests for identification of current and past infection with SARS‐CoV‐2

T Fox, J Geppert, J Dinnes, K Scandrett… - Cochrane database …, 2022 - cochranelibrary.com
Background The diagnostic challenges associated with the COVID‐19 pandemic resulted in
rapid development of diagnostic test methods for detecting SARS‐CoV‐2 infection. Serology …

Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays

A La Marca, M Capuzzo, T Paglia, L Roli… - Reproductive …, 2020 - Elsevier
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its associated
coronavirus disease 2019 (COVID-19) pandemic has demanded rapid upscaling of in-vitro …

COVID-19 antibody tests and their limitations

G Liu, JF Rusling - ACS sensors, 2021 - ACS Publications
COVID-19, caused by the SARS-CoV-2 virus, has developed into a global health crisis,
causing over 2 million deaths and changing people's daily life the world over. Current main …

Interleukin-6 as prognosticator in patients with COVID-19

E Grifoni, A Valoriani, F Cei, R Lamanna… - Journal of …, 2020 - journalofinfection.com
The recurrence of seasonal influenza epidemics is attributed to the continuous evolution of
influenza viruses, which enables them to change pathogenicity and escape from human …

Early detection of SARS-CoV-2 seroconversion in humans with aggregation-induced near-infrared emission nanoparticle-labeled lateral flow immunoassay

R Chen, C Ren, M Liu, X Ge, M Qu, X Zhou, M Liang… - ACS …, 2021 - ACS Publications
An outbreak of coronavirus disease (COVID-19) caused by severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) poses great threats to human health and the …

Microfluidics-based point-of-care testing (POCT) devices in dealing with waves of COVID-19 pandemic: the emerging solution

A Kumar, A Parihar, U Panda… - ACS applied bio …, 2022 - ACS Publications
Recent advances in microfluidics-based point-of-care testing (POCT) technology such as
paper, array, and beads have shown promising results for diagnosing various infectious …

Lack of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a large cohort of previously infected persons

LR Petersen, S Sami, N Vuong… - Clinical Infectious …, 2021 - academic.oup.com
Background Reports suggest that some persons previously infected with severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2) lack detectable immunoglobulin G (IgG) …

[HTML][HTML] Anti-spike, anti-nucleocapsid and neutralizing antibodies in SARS-CoV-2 inpatients and asymptomatic individuals

E Brochot, B Demey, A Touzé, S Belouzard… - Frontiers in …, 2020 - frontiersin.org
A better understanding of the anti-SARS-CoV-2 immune response is necessary to finely
evaluate commercial serological assays but also to predict protection against reinfection and …

A comparative review of immunoassays for COVID-19 detection

E Mohit, Z Rostami, H Vahidi - Expert review of clinical immunology, 2021 - Taylor & Francis
Introduction: The gold standard for diagnosis of coronavirus disease 2019 (COVID-19) is
detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by reverse …

Temperature-dependent surface stability of SARS-CoV-2

A Kratzel, S Steiner, D Todt, P V'kovski… - Journal of …, 2020 - journalofinfection.com
The recurrence of seasonal influenza epidemics is attributed to the continuous evolution of
influenza viruses, which enables them to change pathogenicity and escape from human …